the heat is on! weisi pei has been approved, and yitong has a bright prospect for listing
2024-09-25
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
recently, the application for the new indication of reducing the risk of cardiovascular events for eton pharmaceuticals' core product, visper (generic name: eicosapentaenoic acid ethyl ester soft capsules), has been officially approved by the national medical products administration (nmpa). as soon as the news came out, eton pharmaceuticals instantly became the focus of the industry, attracting extensive and in-depth attention from the media, and its corporate image and brand influence have been significantly improved. this not only injected strong momentum into eton's ipo, but also demonstrated the stability and bright future of eton's listing journey.
as an innovative product of edding pharmaceuticals in the cardiovascular field, vispas has been proven to be effective in reducing the risk of cardiovascular events in many countries and regions around the world. the drug fills the gap in the treatment of hypertriglyceridemia in china and provides new treatment options for patients with cardiovascular diseases. with the full launch of vispas in the chinese market, edding pharmaceuticals will undoubtedly occupy the commanding heights of the cardiovascular drug market. while helping edding pharmaceuticals expand its ipo scale, its pace of listing will also become more solid.
the reason why eddingpharm has achieved such remarkable achievements is inseparable from its profound industry accumulation and strong core competitiveness. after more than 20 years of intensive cultivation, eddingpharm has built a complete innovative drug research and development system, covering the entire process from drug discovery, preclinical research to clinical trials and registration applications. at the same time, eddingpharm also has high-end production and manufacturing capabilities and global supply chain advantages to ensure the stability and reliability of product quality. in addition, eddingpharm has established an efficient commercial operation network that can quickly capture market trends and accurately meet patient needs. this series of advantages has accelerated eddingpharm's ipo process, and eddingpharm's listing prospects are even more exciting.
at the critical stage of promoting the listing, eddingpharm closely followed the grand blueprint of the outline of healthy china 2030 plan, carefully planned the listing path, and focused on the fields of anti-infection, cardiovascular and other fields with a large patient base and broad diagnosis and treatment space, and unswervingly explored and introduced innovative drugs that can meet china's potential medical needs. this strategic choice is undoubtedly a wise choice for eddingpharm to launch an ipo, with a deep insight into the future trend of market demand, and laid a solid foundation for eddingpharm to move forward steadily after listing.
mr. ni xin, as the helmsman of eddingpharm, showed firm confidence and forward-looking vision for the upcoming listing of eddingpharm. he pointed out: "eddingpharm's road to listing is destined to coexist with opportunities and challenges, but with eddingpharm's comprehensive advantages in innovative drug research and development, production and manufacturing, supply chain management and commercial operations, we are fully capable of actively responding to various challenges, constantly breaking through ourselves, achieving leapfrog development, and bringing more health and well-being to patients around the world."
